These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 15808752)

  • 1. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome.
    Ge L; Iakovou I; Sangiorgi GM; Chieffo A; Melzi G; Cosgrave J; Montorfano M; Michev I; Airoldi F; Carlino M; Corvaja N; Colombo A
    J Am Coll Cardiol; 2005 Apr; 45(7):989-94. PubMed ID: 15808752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group.
    Brodie BR; Wilson H; Stuckey T; Nussbaum M; Laurent S; Bradshaw B; Humphrey A; Metzger C; Hermiller J; Krainin F; Juk S; Cheek B; Duffy P; Simonton CA;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1105-12. PubMed ID: 19926052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seven-year safety and efficacy of the unrestricted use of drug-eluting stents in saphenous vein bypass grafts.
    Nauta ST; Van Mieghem NM; Magro M; Deckers JW; Simsek C; Van Geuns RJ; Van Der Giessen WJ; De Jaegere P; Regar E; Van Domburg RT; Serruys PW
    Catheter Cardiovasc Interv; 2012 May; 79(6):912-8. PubMed ID: 21542111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial 2-years results of drug-eluting stents in saphenous vein graft lesions.
    Assali A; Raz Y; Vaknin-Assa H; Ben-Dor I; Brosh D; Teplitsky I; Fuchs S; Kornowski R
    EuroIntervention; 2008 May; 4(1):108-14. PubMed ID: 19112787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial.
    Brilakis ES; Lichtenwalter C; Abdel-karim AR; de Lemos JA; Obel O; Addo T; Roesle M; Haagen D; Rangan BV; Saeed B; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S
    JACC Cardiovasc Interv; 2011 Feb; 4(2):176-82. PubMed ID: 21349456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions.
    Wöhrle J; Nusser T; Kestler HA; Kochs M; Hombach V
    Clin Res Cardiol; 2007 Feb; 96(2):70-6. PubMed ID: 17146605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Four-year safety and efficacy of the unrestricted use of sirolimus- and paclitaxel-eluting stents in coronary artery bypass grafts.
    van Twisk PH; Daemen J; Kukreja N; van Domburg RT; Serruys PW
    EuroIntervention; 2008 Nov; 4(3):311-7. PubMed ID: 19110803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of long-term outcomes of drug-eluting stents and bare metal stents for saphenous vein graft stenosis.
    Chakravarty T; Morrissey RP; Wertman B; Naghi J; Chou S; Goykhman P; Doctor N; Mirocha J; Forrester JS; Makkar R
    Catheter Cardiovasc Interv; 2012 May; 79(6):903-9. PubMed ID: 21805570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts.
    Gioia G; Benassi A; Mohendra R; Chowdhury K; Masood I; Matthai W
    Catheter Cardiovasc Interv; 2008 Jul; 72(1):13-20. PubMed ID: 18561143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: results from the Prairie "Real World" Stent Registry.
    Goswami NJ; Gaffigan M; Berrio G; Plessa AL; Pfeiffer AM; Markwell SJ; Mishkel GJ
    Catheter Cardiovasc Interv; 2010 Jan; 75(1):93-100. PubMed ID: 19787803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early beneficial effects of drug-eluting stents in vein grafts wane during long term follow-up: a case-control study.
    Pasceri V; Tarsia G; Niccoli G; Viceconte N; Porto I; Leone AM; Trani C; Speciale G; Lisanti P
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1112-7. PubMed ID: 22422701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of sirolimus-eluting stents as compared to paclitaxel-eluting stents for saphenous vein graft intervention.
    Chu WW; Kuchulakanti PK; Wang B; Clavijo LC; Suddath WO; Pichard AD; Satler LF; Kent KM; Waksman R
    J Interv Cardiol; 2006 Apr; 19(2):121-5. PubMed ID: 16650239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term follow-up of drug eluting versus bare metal stents in the treatment of saphenous vein graft lesions.
    Ybarra LF; Ribeiro HB; Pozetti AH; Campos CA; Esper RB; Lemos PA; Lopes AC; Kalil-Filho R; Ellis SG; Ribeiro EE
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):E856-63. PubMed ID: 23239630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.
    Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G
    J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program.
    Brilakis ES; Lasala JM; Cox DA; Berger PB; Bowman TS; Starzyk RM; Dawkins KD
    JACC Cardiovasc Interv; 2010 Jul; 3(7):742-50. PubMed ID: 20650436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial.
    Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Van den Branden F; Van Langenhove G;
    J Am Coll Cardiol; 2007 Jul; 50(3):261-7. PubMed ID: 17631219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of chronic renal insufficiency on clinical outcomes in patients undergoing saphenous vein graft intervention with drug-eluting stents: a multicenter Southern Californian Registry.
    Lee MS; Hu PP; Aragon J; Shah A; Bhatia R; Jones N; Penny W; French W; Tobis J; Mahmud E
    Catheter Cardiovasc Interv; 2010 Aug; 76(2):272-8. PubMed ID: 20623716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of sirolimus-eluting stents with paclitaxel-eluting stents in saphenous vein graft intervention (from a multicenter Southern California Registry).
    Lee MS; Hu PP; Aragon J; Shah AP; Oyama J; Dhoot J; Iqbal Z; Jones N; Penny W; Tobis J; Mahmud E; French W
    Am J Cardiol; 2010 Aug; 106(3):337-41. PubMed ID: 20643242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting stents vs. bare metal stents in saphenous vein graft disease. Insights from a meta-analysis of 7,090 patients.
    Lupi A; Navarese EP; Lazzero M; Sansa M; De Servi S; Serra A; Bongo AS; Buffon A
    Circ J; 2011; 75(2):280-9. PubMed ID: 21173499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease.
    Minutello RM; Bhagan S; Sharma A; Slotwiner AJ; Feldman DN; Cuomo LJ; Wong SC
    J Interv Cardiol; 2007 Dec; 20(6):458-65. PubMed ID: 18042050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.